English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Medicine BioTech
ADC研发浪潮席卷下,四环医药(0460.HK)差异化布局创新
Aug 16, 2022 16:12 HKT
Sirnaomics研发用于优化GalNAc递送平台的肽对接载体(PDoV(TM)),致力于创新siRNA疗法
Aug 16, 2022 12:54 HKT
Sirnaomics研發用於優化GalNAc遞送平台的肽對接載體(PDoV(TM)),致力於創新siRNA療法
Aug 16, 2022 12:53 HKT
Sirnaomics Develops Peptide Docking Vehicle (PDoV(TM)) Designed for an Enhanced GalNAc Delivery Platform for Novel siRNA Therapeutics
Aug 16, 2022 12:52 HKT
亿胜生物荣登「2022年福布斯亚洲中小上市企业200强」
Aug 16, 2022 09:02 HKT
億勝生物榮登「2022年福布斯亞洲中小上市企業200強」
Aug 16, 2022 09:01 HKT
Essex Bio-Technology Included in "Forbes Asia's Best Under A Billion 2022"
Aug 16, 2022 09:00 HKT
打造全球新药发源地 百奥赛图冲刺基因编辑第一股
Aug 11, 2022 17:01 HKT
打造全球新藥發源地 百奧賽圖衝刺基因編輯第一股
Aug 11, 2022 17:00 HKT
悅商集團與集慶生物達成全面戰略合作 取得猴痘病毒檢測試劑盒全球獨家銷售權
Aug 11, 2022 08:50 HKT
Virios Therapeutics: The 'Virus Hypothesis' That Stands to Change the Lives of 10M Americans
Aug 09, 2022 20:30 HKT
노보텍의 유연 근무 정책, 최고 유연 근무 프로그램의 ‘2022년 우수상’ 최종 후보로 선정
Jul 26, 2022 20:00 HKT
The Global Pharmaceutical Industry is Accelerating; Aptorum Group Has Received Orphan Drug Designation from US FDA for Its SACT-1
Jul 26, 2022 14:00 HKT
全球创新药加速发展 知临集团SACT-1已获FDA孤儿药资格认证
Jul 26, 2022 12:09 HKT
全球創新藥加速發展 知臨集團SACT-1已獲FDA孤兒藥資格認證
Jul 26, 2022 12:08 HKT
Sirnaomics RNAi候选药物STP705用于治疗肝癌的I期临床研究IND申请已获台湾卫生福利部批准
Jul 26, 2022 10:57 HKT
Sirnaomics RNAi候選藥物STP705用於治療肝癌的I期臨床研究IND申請已獲台灣衛生福利部批准
Jul 26, 2022 10:56 HKT
Sirnaomics Receives IND Clearance from the Taiwan Ministry of Health and Welfare for Phase I Clinical Study of RNAi Therapeutic STP705 for Liver Cancer Treatment
Jul 26, 2022 10:55 HKT
冠科美博 (Apollomics Inc.) 扩充其领导团队,任命 Jane Wang 博士担任首席科学官一职
Jul 26, 2022 09:19 HKT
冠科美博 (Apollomics Inc.) 擴充其領導團隊,任命 Jane Wang 博士擔任首席科學官一職
Jul 26, 2022 09:18 HKT
<< Previous  Next >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: